QT-prolonging agents with risk of torsades de pointes

Abstract

Get full access to this article

View all access options for this article.

References

Berling

Rahul

Bjorksten

et al . A review of ECG and QT interval measurement use in a public psychiatric inpatient setting. Australas Psychiatry 2018; 25: 50–55.

Danielsson

Collin

Bergman

et al . Antidepressants and antipsychotics classiﬁed with torsades de pointes arrhythmia risk and mortality in older adults – a Swedish nationwide study. Br J Clin Pharmacol 2015; 81: 773–783.

Tisdale

. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Can Pharm J (Ott) 2016; 148: 139–152.

Hoehns

Stanford

Geraets

et al . Torsades de pointes associated with chlorpromazine: Case report and review of associated ventricular arrhythmias Pharmacotherapy 2001; 21: 871–883.

Leonard

Freeman

Newcomb

et al . Antipsychotics and the risks of sudden cardiac death and all-cause death: cohort studies in Medicaid and dually-eligible Medicaid-Medicare beneficiaries of five states. J Clin Exp Cardiolog 2013; 10: 1–9.